Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma

Journal of Gastroenterology

Volumn 45, Issue 11, 2010, Pages 1146-1154

  Yamagishi, Yoshiyuki ^a   Higuchi, Hajime ^a   Izumiya, Motoko ^a   Sakai, Gen ^a   Iizuka, Hideko ^a   Nakamura, Shoko ^a   Adachi, Masayuki ^a   Hozawa, Sigenari ^a   Takaishi, Hiromasa ^a   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CA19 9; Dupan 2; Elderly; Gemcitabine; Neoplasm; Pancreas; Unresectable

Indexed keywords

GEMCITABINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CONTROLLED STUDY; CYTOPENIA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GERIATRIC PATIENT; HUMAN; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; PANCREAS CARCINOMA; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BONE MARROW; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 78651275179     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-010-0258-9     Document Type: Article

References (23)

1. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet. 1997;349:485-489.
2. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23-47.
3. Heinemann V. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol. 2002;29:9-16.
4. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
5. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
6. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25:2212-2217.
7. National Cancer Institute (US) Surveillance program. SEER cancer statistics review: tables and graphs. 1989.
8. Marugame T, Matsuda T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2001 based on the data from 10 population-based cancer registries. Jpn J Clin Oncol. 2007;37:884-891. (Pubitemid 350259009)
9. Martin C, Ardizzoni A, Rosso R. Gemcitabine: safety profile and efficacy in non-small cell lung cancer unaffected by age. Aging (Milano). 1997;9:297-303.
10. Hanada K, Hino F, Amano H, Fukuda T, Kuroda Y. Current treatment strategies for pancreatic cancer in the elderly. Drugs Aging. 2006;23:403-410.
11. Maréchal R, Demols A, Gay F, de Maertelaer V, Arvanitaki M, Hendlisz A, et al. Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer. Pancreas. 2008;36:e16-e21.
12. Morita T, Akechi T, Ikenaga M, Kizawa Y, Kohara H, Mukaiyama T, et al. Communication about the ending of anticancer treatment and transition to palliative care. Ann Oncol. 2004;15:1551-1557.
13. Shepherd FA, Abratt RP, Anderson H, Gatzemeier U, Anglin G, Iglesias J. Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Semin Oncol. 1997;24:S7- 50-55.
14. Begg CB, Carbone PP. Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer. 1983;52:1986-1992.
15. Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1997;80:286-291.
16. Gupta N, Ahmed I, Steinberg H, Patel D, Nissel-Horowitz S, Mehrotra B. Gemcitabine-induced pulmonary toxicity: case report and review of the literature. Am J Clin Oncol. 2002;25:96-100.
17. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology. 2005;68:171-178.
18. Hayashi K, Imaizumi T, Uchida K, Kuramochi H, Takasaki K. High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1. Oncol Rep. 2002;9:1355-1361.
19. Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, et al.A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2009;63(2):313-319.
20. Lundin J, Roberts PJ, Kuusela P, Haglund C. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer. 1994;69:515-519.
21. Katz A, Hanlon A, Lanciano R, Hoffman J, Coia L. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41:393-396.
22. Halm U, Schumann T, Schiefke I, Witzigmann H, Mossner J, Keim V. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer. 2000;82:1013-1016.
23. Ziske C, Schlie C, Gorschluter M, Glasmacher A, Mey U, Strehl J, et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer. 2003;89:1413-1417.